Bitcoin Falls Below $62,000; Bittensor, dogwifhat Among Top Losers

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices falling below the key $62,000 level on Wednesday. Ethereum (CRYPTO: ETH) also recorded losses, but remained above the key $3,000 mark this morning.

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices falling below the key $62,000 level on Wednesday.

Ethereum (CRYPTO: ETH) also recorded losses, but remained above the key $3,000 mark this morning.

THORChain (CRYPTO: RUNE) was the top gainer over the prior 24 hours, while Bittensor (CRYPTO: TAO) turned out to be the biggest loser.

At the time of writing, the global crypto market cap fell to $2.28 trillion, recording a 24-hour decline of 2.7%. BTC was trading lower by 2.5% at $61,870 while ETH fell by around 2.1% to $3,005 on Wednesday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers                                                

THORChain (CRYPTO: RUNE)

  • Price: $5.67
  • 24-hour gain: 8.5%

Lido DAO (CRYPTO: LDO)

  • Price: $1.99    
  • 24-hour gain: 2.1%

UNUS SED LEO (CRYPTO: LEO)

  • Price: $5.90
  • 24-hour gain: 1.8%

TRON (CRYPTO: TRX)

  • Price: $0.1225
  • 24-hour gain: 1.8%

Ethena (CRYPTO: ENA)

  • Price: $0.9042
  • 24-hour gain: 1.2%

Losers

Bittensor (CRYPTO: TAO)

  • Price: $377.36 
  • 24-hour drop: 14.9%

dogwifhat (CRYPTO: WIF)

  • Price: $2.88                
  • 24-hour drop: 11.4%

Helium (CRYPTO: HNT)

  • Price: $4.80
  • 24-hour drop: 8.4%

JasmyCoin (CRYPTO: JASMY)

  • Price: $0.01776
  • 24-hour drop: 7.6%

SingularityNET (CRYPTO: AGIX)

  • Price: $0.9211
  • 24-hour drop: 7.1%

Read This Next: Top 3 Industrial Stocks That May Rocket Higher This Quarter

Total
0
Shares
Related Posts
Read More

Why Ocugen Stock Is Climbing Today

Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen said the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 has  approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

OCGN